Huadong Pharmaceutical announced that its wholly-owned subsidiary Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. received the “Drug Clinical Trial Approval Notice” approved and issued by the State Drug Administration, and the HDP-101 clinical trial application developed by China and US Huadong in cooperation with German shareholding company Heidelberg Pharma AG was approved. HDP-101 is a novel ADC drug used to treat B-cell mature antigen-positive clonal hematologic diseases such as relapsed/refractory multiple myeloma.

Zhitongcaijing · 10/15 09:41
Huadong Pharmaceutical announced that its wholly-owned subsidiary Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. received the “Drug Clinical Trial Approval Notice” approved and issued by the State Drug Administration, and the HDP-101 clinical trial application developed by China and US Huadong in cooperation with German shareholding company Heidelberg Pharma AG was approved. HDP-101 is a novel ADC drug used to treat B-cell mature antigen-positive clonal hematologic diseases such as relapsed/refractory multiple myeloma.